Can-Fite BioPharma Cash Flow Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2010
Net Income	-7.63	-7.63	-10.17	-12.62	-14.44	-12.63	Upgrade
Depreciation & Amortization	0.11	0.11	0.07	0.07	0.02	0.01	Upgrade
Share-Based Compensation	0.26	0.26	0.26	0.47	0.36	0.39	Upgrade
Other Operating Activities	-1.18	-1.18	-0.96	2.22	2	1.14	Upgrade
Operating Cash Flow	-8.44	-8.44	-10.8	-9.86	-12.06	-11.08	Upgrade
Capital Expenditures	-0	-0	-0.01	-0.01	-0.03	-0	Upgrade
Change in Investments	0.5	0.5	9.51	-14.5	0	0	Upgrade
Investing Cash Flow	0.5	0.5	9.5	-14.51	-0.03	-0	Upgrade
Share Issuance / Repurchase	9.14	9.14	0	20.46	17.68	10.17	Upgrade
Financing Cash Flow	9.14	9.14	0	20.46	17.68	10.17	Upgrade
Exchange Rate Effect	0.1	0.1	-0.11	0.03	-0.02	0	Upgrade
Net Cash Flow	1.3	1.3	-1.41	-3.88	5.57	-0.92	Upgrade
Free Cash Flow	-8.44	-8.44	-10.81	-9.87	-12.09	-11.09	Upgrade
Free Cash Flow Margin	-1136.20%	-1136.20%	-1334.57%	-1156.98%	-1584.40%	-545.62%	Upgrade
Free Cash Flow Per Share	-1.98	-1.98	-3.98	-5.35	-10.12	-38.72	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).